Megan Doyle McClam, MD
Pulmonary Disease · Anderson, SCNPI 1740644343
Payments from drug & device makers
Across 145 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$552
- GSK$480
- Regeneron Healthcare Solutions, Inc.$326
- Boehringer Ingelheim$319
- Takeda Pharmaceuticals U.S.A., Inc.$202
- Sanofi$165
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,062100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $552 |
| GSK | 34 | $480 |
| Regeneron Healthcare Solutions, Inc. | 8 | $326 |
| Boehringer Ingelheim | 15 | $319 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $202 |
| Sanofi | 5 | $165 |
| Merck | 9 | $149 |
| Actelion Pharmaceuticals US, Inc. | 5 | $115 |
| Grifols USA, LLC | 4 | $101 |
| Baxter Healthcare | 3 | $74 |
| Amgen | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| CSL Behring | 2 | $48 |
| Mylan Specialty L.p. | 3 | $42 |
| AbbVie | 2 | $37 |
| Insmed, Inc. | 2 | $35 |
| Viatris Specialty LLC | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $30 |
| United Therapeutics Corporation | 1 | $26 |
| Philips North America LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Covis Pharma GmbH | 1 | $20 |
| Pfizer | 1 | $19 |
| Verona Pharma, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$124
How this compares
$3,062 in reported general payments places this provider in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 373 | $289,374 |
| OfevNintedanib Esylate | 12 | $155,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 192 | $126,343 |
| XolairOmalizumab | 22 | $94,171 |
| SymbicortBudesonide/Formoterol Fumarate | 115 | $32,291 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $23,205 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $16,423 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $15,541 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $13,724 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 465 | $12,144 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $7,011 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $6,262 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,878 |
| Wixela InhubFluticasone Propion/Salmeterol | 50 | $4,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $480 | $332,181476 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $319 | $201,00568 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $552 | $165,644325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Anderson
- Charles ThompsonAnderson$7.7M
- Abhijit RavalAnderson$3M
- Kenneth WaltersAnderson$81K
- Syed MalikAnderson$10K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- David ErbSpartanburg$7.5M
- Richard BoganColumbia$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.